Jefferies Initiates Coverage On Mentari Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsInitiationPrice Target
Jefferies analyst Andrew Tsai initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Buy rating and announces Price Target of $30.
Jefferies analyst Andrew Tsai initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Buy rating and announces Price Target of $30.